RO7790121
Phase 1Active 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout RO7790121
RO7790121 is a phase 1 stage product being developed by Roche for MASH. The current trial status is active. This product is registered under clinical trial identifier NCT06903065. Target conditions include MASH.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06903065 | Phase 1 | Active |
Competing Products
6 competing products in MASH
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY3849891 + Placebo | Eli Lilly | Phase 1 | 33 |
| Placebo + IBI362 | Innovent Biologics | Phase 2 | 51 |
| ALN-HSD + Placebo | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Resmetirom + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |
| Denifanstat + Placebo | Sagimet Biosciences | Phase 3 | 69 |
| TVB-2640 25 mg (US) + TVB-2640 50 mg (US) + Placebo (US) + TVB-2640 50 mg (China) + Placebo (China) + TVB-2640 75 mg (US) | Sagimet Biosciences | Phase 2 | 44 |